A case study: Surface contamination of cyclophosphamide due to working practices and cleaning procedures in two Italian hospitals

Annals of Occupational Hygiene

Volumn 49, Issue 7, 2005, Pages 611-618

  Acampora, Antonio ^a   Castiglia, Loredana ^a   Miraglia, Nadia ^a,b   Pieri, Maria ^a,b   Soave, Claudio ^c   Liotti, Francesco ^b   Sannolo, Nicola ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Cyclophosphamide; Environmental monitoring; Wipe test; Working conditions

Indexed keywords

BIOMARKERS; CLEANING; DOOR HANDLES; HOSPITALS; LAMINAR FLOW; MONITORING; PERSONNEL TRAINING; PHOSPHORUS COMPOUNDS; RISK MANAGEMENT; SODIUM COMPOUNDS; TOXICITY;

CYCLOPHOSPHAMIDE; ENVIRONMENTAL MONITORING; WIPE TESTS; WORKING CONDITIONS;

CONTAMINATION;

CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; HYPOCHLORITE SODIUM;

ARTICLE; CLEANING; DRUG CONTAMINATION; DRUG DETERMINATION; DRUG EXPOSURE; ENVIRONMENTAL MONITORING; GAS CHROMATOGRAPHY; HOSPITAL; LAMINAR AIRFLOW; MASS SPECTROMETRY; ONCOLOGY; PRIORITY JOURNAL; QUESTIONNAIRE; RISK MANAGEMENT; SHIFT WORKER; STORAGE; WARD; WORKPLACE;

ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; DECONTAMINATION; ENVIRONMENTAL MONITORING; EQUIPMENT CONTAMINATION; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HOSPITAL UNITS; HUMANS; IFOSFAMIDE; ITALY; MALE; NURSING STAFF, HOSPITAL; OCCUPATIONAL EXPOSURE; WORKPLACE;

EID: 26644453614     PISSN: 00034878     EISSN: 14753162     Source Type: Journal    
DOI: 10.1093/annhyg/mei029     Document Type: Article

References (26)

1. Allwood M, Stanley A, Wright P. (2002) The cytotoxics handbook, 4th edn. Rodcliffe Medical Press Ud, Abingdon, Oxon.
2. American Society of Hospital Pharmacists. (1990) ASHP Technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm; 47: 1033-9.
3. Baxter PJ. (1991) Research in occupational health. The UK National Health Service. J Soc Occup Med; 41: 7-9.
4. Black DJ, Livingston RB. (1990a) Antineoplastic drugs in 1990. A review. Drugs; 39: 489-501.
5. Black DJ, Livingston RB. (1990b) Antineoplastic drugs in 1990. A review. Drugs; 39: 652-73.
6. Canadian Society of Hospital Pharmacists. (1981) Guidelines for the handling of hazardous pharmaceuticals. Can J Hosp Pharm; 34: 126-8.
7. D.Lgs. 19 September 1994, n.626 [Legislative Decree] (Italian). Available from: http://www.amblav.it.
8. D.Lgs. 25 February 2000, n. 66 [Legislative Decree. Workers protection about risks from the exposure to carcinogenic or mutagenic agents] (Italian). Protezione dei lavoratori circa i rischi derivanti dall'esposizione ad agenti cancerogeni o mutageni. Available from: http://www.amblav.it.
9. D.Lgs. 2 February 2002, n.25 [Legislative Decree. Updating of D.Lgs. 626/94: protective measures about carcinogenic and mutagenic agents] (Italian). Aggiornamento 2002 del Titolo VII del D. Lgs. 626/94: protezione ad agenti cancerogeni e/o mutageni. Available from: http://www.amblav.it.
10. Goodman I. (1998) Clinical practice guidelines: the administration of cytotoxic chemotherapy. Technical report. Oxford: Royal College of Nursing.
11. G.U. n. 236, 07/10/1999 [Safety and Hygiene. National Document] (Italian) Sicurezza e Igiene del Lavoro. Documento di Origine Nazionale.
12. Hirst M, Tse S, Mills DG et al. (1984) Occupational exposure to cyclophosphamide. Lancet; 1: 186-8.
13. I.S.P.E.S.L., Istituto Superiore per la Prevenzione e la Sicurezza sul Lavoro (Institute for Labour Safety and Prevention). Guidelines for the safety and the healthcare of workers exposed to antineoplastic drugs in hospitals (Italian) 5 August 1999.
14. Minoia C, Turci R, Sottani C. (1999a) Risk assessment concerning hospital personnel participating in the preparation and administration of antineoplastic drugs. (Article in Italian) G Ital Med Lav Ergon; 21: 93-107.
15. Minoia C, Turci R, Sottani C et al. (1999b) Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Rapid Commun Mass Spectrom; 12: 1485-93.
16. Otto T, Rubben H. (2004) Prevention of bladder cancer. Urologe A; 43: 56-4.
17. Perico A, Lorini C, Biliotti T et al. (2003) Evaluation of professional exposure to antiblastic chemotherapeutic agents in a Tuscan hospital environment. Ann Ig; 15: 363-71.
18. Rogers B. (1987) Health hazards to personnel handling antineoplastic agents. Occup Med; 2: 513-24.
19. Sannolo N, Miraglia N, Biglietto M et al. (1999) Determination of cyclophosphamide and ifosphamide in urine at trace levels by gas chromatography/tandem mass spectrometry. J Mass Spectrom; 34: 845-9.
20. Schmaus G, Schierl R, Funck S. (2002) Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry. Am J Health Syst Pharm; 59: 956-61.
21. Sessink PJ, Boer KA, Scheefhals AP et al. (1992) Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health; 64: 105-12.
22. Sessink PJ, Kroese ED, van Kranen HJ et al. (1995) Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health; 67: 317-23.
23. Sessink PJ, Wittenhorst BC, Anzion RB et al. (1997) Exposure of pharmacy technicians to antineoplastic agents: revaluation after additional protective measures. Arch Environ Health; 52: 240-4.
24. Stahlmann R, Bluth U, Neubert D. (1985) Effects of the cyclophosphamide metabolite acrolein in mammalian limb bud cultures. Arch Toxicol; 57: 163-7.
25. US Food and Drug Administration: Center for Drug Evaluation and Research. (2001) Guidance for industry: bioanalytical method validation. Available from: www.fda.gov/cder/guidance/4252fnl.htm.
26. Ziegler E, Mason HJ, Baxter PJ. (2002) Occupational exposure to cytotoxic drugs in two UK oncology wards. Occup Environ Med; 59: 608-12.